Erasca Inc Aktie News

Erasca's general counsel and corporate secretary sold 120,000 shares of the biotech for $670,800 in gross proceeds on Jan. 7. The sale resulted from an option exercise with shares immediately sold; no indirect holdings or gifts were involved.

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California.

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Mana...

U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities...

The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043  Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerciali...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investo...

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in N...